The FDA on June 8, 2018 granted regular approval to VENCLEXTA® for patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. VENCLEXTA® is a product of AbbVie Inc. and Genentech Inc.
Bottom Ad
Advertisement
Subscribe
